GLAXO
500660Corrigendum To The Notice Of Postal Ballot Dated August 3, 2026
As per attachment
GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma), a subsidiary of the global healthcare leader GSK plc, is a prominent player in the Indian pharmaceutical industry. Established in 1924, the company specializes in manufacturing, marketing, and distributing prescription medicines and vaccines spanning therapeutic areas such as respiratory, vaccines, anti-infectives, dermatology, oncology, gastroenterology, and endocrinology. GSK Pharma's footprint covers pan-India operations, leveraging a robust supply chain, multicity manufacturing units, and an extensive distribution network supporting both urban and rural healthcare needs.
Corrigendum To The Notice Of Postal Ballot Dated August 3, 2026
As per attachment
Volume Movement Letter
As per attachment
Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Disclosure Under Regulation 30
As per attachment
Announcement under Regulation 30 (LODR)-Newspaper Publication
As per attachment
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
As per attachment
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript
Disclosure Under Regulation 30
IT Refund of Rs 52 crores
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
As per attachment
Announcement under Regulation 30 (LODR)-Newspaper Publication
As per attachment
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
As per attachment
Announcement under Regulation 30 (LODR)-Change in Management
Reappointment of Managing Director
Announcement under Regulation 30 (LODR)-Resignation of Director
As per attachment
Announcement under Regulation 30 (LODR)-Change in Directorate
As per attachment
Announcement under Regulation 30 (LODR)-Press Release / Media Release
As per attachment
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Presentation
Results For Quarter 30Th June 2026
Outcome of meeting
Board Meeting Outcome for Outcome Of Meeting
Outcome of Meeting
GlaxoSmithKline Pharmaceuticals Ltd
About
GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma), a subsidiary of the global healthcare leader GSK plc, is a prominent player in the Indian pharmaceutical industry. Established in 1924, the company specializes in manufacturing, marketing, and distributing prescription medicines and vaccines spanning therapeutic areas such as respiratory, vaccines, anti-infectives, dermatology, oncology, gastroenterology, and endocrinology. GSK Pharma's footprint covers pan-India operations, leveraging a robust supply chain, multicity manufacturing units, and an extensive distribution network supporting both urban and rural healthcare needs.
Renowned for bringing innovative healthcare solutions to the Indian market, GSK Pharma collaborates with government and healthcare providers to support immunization drives and improve public health outcomes. The company’s portfolio is continually refreshed through local launches of global pipeline assets, ensuring access to the latest therapies addressing unmet medical needs.
Business Model & Strategy
GSK Pharma's revenue model centers on the discovery, development, manufacturing, and marketing of branded prescription pharmaceuticals and vaccines. It earns revenues through sales to hospitals, clinics, retailers, and through tender-based business with governmental bodies. The company supplements its Indian manufacturing with imports of strategic products from global GSK facilities to meet demand and regulatory mandates.
Strategic growth levers include regular introduction of new molecular entities and vaccines, strong lifecycle management of existing brands, digital engagement with healthcare professionals, and expansion into high-growth therapeutic segments. The company invests in medical education, awareness campaigns, and strategic collaborations to broaden its reach and market penetration.
Management Overview
9 MembersMs.Renu Sud Karnad
Non-Executive - Non Independent Director-ChairpersonMs.Sunita Maheshwari
Non-Executive - Independent DirectorMr.Manu Anand
Non-Executive - Independent DirectorMr.Somasundaram Palamadairamaswamy
Non-Executive - Independent DirectorMr.Anup Wadhawan
Non-Executive - Independent DirectorMr.Bhushan Akshikar
Executive DirectorMr.JubyChandy
Executive DirectorMr.Subesh Williams
Non-Executive - Non Independent DirectorMr.AjayANadkarni
Company Secretary & Compliance OfficerAwards & Recognition
4 Awards- Ranked among India's Top 10 Multinational Pharmaceutical Companies (ET PharmaWorld Awards, 2024)
- Included in 'India's Most Trusted Brands' survey (Brand Trust Report, 2024)
- Featured in the S&P Global Sustainability Yearbook 2024 for ESG performance
- Recognized for contribution to India's Universal Immunization Programme (MOHFW appreciation, 2023)
Market Information
Company Timeline
100+ Years of Excellence | 7 Major Milestones
Company founded in India
Listed on the Bombay Stock Exchange
Merger with SmithKline Beecham Pharmaceuticals (India) Ltd
Expansion of vaccine manufacturing and launch of key vaccines
Completion of global asset swap between GSK and Novartis, strengthening vaccines portfolio
Digital transformation of salesforce and doctor engagement platforms
Launch of new respiratory and anti-infective therapies; recognition for ESG initiatives
The Next Evolution
Contact Information
Registered Office
GSK House, Dr Annie Besant Road, Worli
Tel: 022-24959595,
Fax: 022-24981526 / 24959494,
Email: askus@gsk.com; ajay.a.nadkarni@gsk.com
Website: india-pharma.gsk.com
Corporate Actions
16| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹57 per share | 29 May 2026 Friday | 29 May 2026 Friday | - | - |
Final Dividend ₹42 per share | 30 May 2025 Friday | 30 May 2025 Friday | - | - |
Interim Dividend ₹12 per share | 07 Nov 2024 Thursday | 07 Nov 2024 Thursday | - | - |
Final Dividend ₹32 per share | 31 May 2024 Friday | 31 May 2024 Friday | - | - |
Final Dividend ₹32 per share | 30 Jun 2023 Friday | 30 Jun 2023 Friday | - | - |
Special Dividend ₹60 per share | 07 Jul 2022 Thursday | 08 Jul 2022 Friday | - | - |
Dividend ₹30 per share | 07 Jul 2022 Thursday | 08 Jul 2022 Friday | - | - |
Dividend ₹30 per share | 19 Jul 2021 Monday | 20 Jul 2021 Tuesday | - | - |
Special Dividend ₹20 per share | 17 Jul 2020 Friday | 20 Jul 2020 Monday | - | - |
Final Dividend ₹20 per share | 17 Jul 2020 Friday | 20 Jul 2020 Monday | - | - |
Dividend ₹20 per share | 11 Jul 2019 Thursday | - | 15 Jul 2019 Monday | 22 Jul 2019 Monday |
Bonus issue 1:1 | 11 Sep 2018 Tuesday | 13 Sep 2018 Thursday | - | - |
Dividend ₹35 per share | 13 Jul 2018 Friday | - | 17 Jul 2018 Tuesday | 24 Jul 2018 Tuesday |
Dividend ₹30 per share | 14 Jul 2017 Friday | - | 18 Jul 2017 Tuesday | 25 Jul 2017 Tuesday |
Dividend ₹50 per share | 15 Jul 2016 Friday | - | 19 Jul 2016 Tuesday | 28 Jul 2016 Thursday |
Dividend ₹62.50 per share | 23 Jul 2015 Thursday | - | 25 Jul 2015 Saturday | 31 Jul 2015 Friday |
₹50,771 Cr.
₹2,997
₹3,121 / 2,088
48.33
₹134.86
22.22
₹62.01
₹10.00
1.9 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 3,230 | 3,303 | 3,309 | 3,354 | 3,352 | 3,576 | 3,895 | 3,967 | 4,100 |
| Expenses | - | - | - | 2,576 | 2,656 | 2,586 | 2,586 | 2,515 | 2,617 | 2,640 | 2,582 | 2,671 |
| Profit | - | - | - | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 | 1,068 |
| Tax | - | - | - | 237 | 213 | 192 | 398 | 229 | 226 | 332 | 370 | 381 |
| EPS | - | - | - | 26 | 6 | 21 | 22 | 36 | 35 | 55 | 55 | 14 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 3,911 | 3,136 | 3,113 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 | - |
| Equity And Liabilities | - | - | - | 3,911 | 3,136 | 3,113 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 06 Apr '19 | Mar 2020 13 Apr '20 | Mar 2021 06 Apr '21 | Mar 2022 19 May '22 | Mar 2023 11 Apr '23 | Mar 2024 04 Apr '24 | Mar 2025 17 Apr '25 | Mar 2026 10 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | - |
| Non Institutions | - | - | - | 12.47% | 13.33% | 12.56% | 12.09% | 12.43% | 13.62% | 12.69% | 12.69% | - |
| FII | - | - | - | - | - | - | - | 2.28% | 3.48% | 4.52% | 4.62% | - |
| DII | - | - | - | - | - | - | - | 10.30% | 7.90% | 7.79% | 7.68% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma), a subsidiary of the global healthcare leader GSK plc, is a prominent player in the Indian pharmaceutical industry. Established in 1924, the company specializes in manufacturing, marketing, and distributing prescription medicines and vaccines spanning therapeutic areas such as respiratory, vaccines, anti-infectives, dermatology, oncology, gastroenterology, and endocrinology. GSK Pharma's footprint covers pan-India operations, leveraging a robust supply chain, multicity manufacturing units, and an extensive distribution network supporting both urban and rural healthcare needs.
Renowned for bringing innovative healthcare solutions to the Indian market, GSK Pharma collaborates with government and healthcare providers to support immunization drives and improve public health outcomes. The company’s portfolio is continually refreshed through local launches of global pipeline assets, ensuring access to the latest therapies addressing unmet medical needs.
GSK Pharma's revenue model centers on the discovery, development, manufacturing, and marketing of branded prescription pharmaceuticals and vaccines. It earns revenues through sales to hospitals, clinics, retailers, and through tender-based business with governmental bodies. The company supplements its Indian manufacturing with imports of strategic products from global GSK facilities to meet demand and regulatory mandates.
Strategic growth levers include regular introduction of new molecular entities and vaccines, strong lifecycle management of existing brands, digital engagement with healthcare professionals, and expansion into high-growth therapeutic segments. The company invests in medical education, awareness campaigns, and strategic collaborations to broaden its reach and market penetration.
Ranked among India's Top 10 Multinational Pharmaceutical Companies (ET PharmaWorld Awards, 2024)
Included in 'India's Most Trusted Brands' survey (Brand Trust Report, 2024)
Featured in the S&P Global Sustainability Yearbook 2024 for ESG performance
Recognized for contribution to India's Universal Immunization Programme (MOHFW appreciation, 2023)
Company founded in India
Listed on the Bombay Stock Exchange
Merger with SmithKline Beecham Pharmaceuticals (India) Ltd
Expansion of vaccine manufacturing and launch of key vaccines
Completion of global asset swap between GSK and Novartis, strengthening vaccines portfolio
Digital transformation of salesforce and doctor engagement platforms
Launch of new respiratory and anti-infective therapies; recognition for ESG initiatives
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon